PLGA Microspheres as new strategy to improve the efficiency of venom immunotherapy

Detalhes bibliográficos
Autor(a) principal: Trindade, R eginaldo Almeida da
Data de Publicação: 2017
Outros Autores: Sant’Anna, Osvaldo Augusto Brazil Esteves, Rescia, Vanessa Cristina, Bruni, Fernanda Miriani, Lopes-Ferreira, Mônica Valdyrce dos Anjos, Santos, Daiane Fernanda dos, Nicolete, Roberto, Faccioli, Lucia Helena, Araujo, Pedro Soares de, Costa, Maria Helena Bueno da
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da Universidade Federal do Ceará (UFC)
Texto Completo: http://www.repositorio.ufc.br/handle/riufc/26626
Resumo: Background: Despite considerable knowledge of allergy and its physiopathology, the only treatment with long - lasting effects for bee venom (BV) allergic patients is venom immunotherapy (VIT). Its efficiency has been recognized worldwide for many years. Howe ver, some limitations still result in patient rejection and prevent its use, such as the long treatment period with a total of 30 - 80 injections administered over three to five years, the high cost of treatment, and the risk of anaphylaxis as a side effect. Objective: In order to overcome these inconveniences, a new formulation for VIT is proposed, consisting of BV encapsulated within microspheres composed of poly - lactide - co - glycolide (MS - PLGA) as a controlled delivery system. Methods: BV - MS - PLGA was prepare d by a double emulsion/solvent evaporation method and its biological efficiency was tested by ex vivo macrophage uptake stimuli and in vivo antibody production in mice. Results: BV - MS - PLGA formulations prevented inflammatory reactions by impeding direct co ntact between BV and the organism/tissue. The increased phagocytosis rate of BV - MS - PLGAs by macrophages allowed for the delivery of antigens directly to the intracellular environment. Furthermore, with the use of BV - MS - PLGAs, antibody production was compar able to traditional VIT (free BV delivered in PBS) with the advantages of protecting the organism against the deleterious effects of BV toxins and reducing the number of injections needed to produce the same protective effect. Conclusion: MS - PLGA is a prom ising controlled delivery system to deliver BV for VIT.
id UFC-7_f93df618973e8fdbccb602b73432e284
oai_identifier_str oai:repositorio.ufc.br:riufc/26626
network_acronym_str UFC-7
network_name_str Repositório Institucional da Universidade Federal do Ceará (UFC)
repository_id_str
spelling PLGA Microspheres as new strategy to improve the efficiency of venom immunotherapyHipersensibilidadeHypersensitivityImunoterapiaImmunotherapyBackground: Despite considerable knowledge of allergy and its physiopathology, the only treatment with long - lasting effects for bee venom (BV) allergic patients is venom immunotherapy (VIT). Its efficiency has been recognized worldwide for many years. Howe ver, some limitations still result in patient rejection and prevent its use, such as the long treatment period with a total of 30 - 80 injections administered over three to five years, the high cost of treatment, and the risk of anaphylaxis as a side effect. Objective: In order to overcome these inconveniences, a new formulation for VIT is proposed, consisting of BV encapsulated within microspheres composed of poly - lactide - co - glycolide (MS - PLGA) as a controlled delivery system. Methods: BV - MS - PLGA was prepare d by a double emulsion/solvent evaporation method and its biological efficiency was tested by ex vivo macrophage uptake stimuli and in vivo antibody production in mice. Results: BV - MS - PLGA formulations prevented inflammatory reactions by impeding direct co ntact between BV and the organism/tissue. The increased phagocytosis rate of BV - MS - PLGAs by macrophages allowed for the delivery of antigens directly to the intracellular environment. Furthermore, with the use of BV - MS - PLGAs, antibody production was compar able to traditional VIT (free BV delivered in PBS) with the advantages of protecting the organism against the deleterious effects of BV toxins and reducing the number of injections needed to produce the same protective effect. Conclusion: MS - PLGA is a prom ising controlled delivery system to deliver BV for VIT.Journal of Chemical and Pharmaceutical Research2017-10-13T14:48:29Z2017-10-13T14:48:29Z2017info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfTRINDADE, R. A. da et al. PLGA microspheres as new strategy to improve the efficiency of venom immunotherapy. Journal of Chemical and Pharmaceutical Research, v. 9, n. 3, p. 197-208, 2017.0975 - 7384http://www.repositorio.ufc.br/handle/riufc/26626Trindade, R eginaldo Almeida daSant’Anna, Osvaldo Augusto Brazil EstevesRescia, Vanessa CristinaBruni, Fernanda MirianiLopes-Ferreira, Mônica Valdyrce dos AnjosSantos, Daiane Fernanda dosNicolete, RobertoFaccioli, Lucia HelenaAraujo, Pedro Soares deCosta, Maria Helena Bueno daengreponame:Repositório Institucional da Universidade Federal do Ceará (UFC)instname:Universidade Federal do Ceará (UFC)instacron:UFCinfo:eu-repo/semantics/openAccess2019-01-25T14:27:27Zoai:repositorio.ufc.br:riufc/26626Repositório InstitucionalPUBhttp://www.repositorio.ufc.br/ri-oai/requestbu@ufc.br || repositorio@ufc.bropendoar:2024-09-11T18:47:18.865380Repositório Institucional da Universidade Federal do Ceará (UFC) - Universidade Federal do Ceará (UFC)false
dc.title.none.fl_str_mv PLGA Microspheres as new strategy to improve the efficiency of venom immunotherapy
title PLGA Microspheres as new strategy to improve the efficiency of venom immunotherapy
spellingShingle PLGA Microspheres as new strategy to improve the efficiency of venom immunotherapy
Trindade, R eginaldo Almeida da
Hipersensibilidade
Hypersensitivity
Imunoterapia
Immunotherapy
title_short PLGA Microspheres as new strategy to improve the efficiency of venom immunotherapy
title_full PLGA Microspheres as new strategy to improve the efficiency of venom immunotherapy
title_fullStr PLGA Microspheres as new strategy to improve the efficiency of venom immunotherapy
title_full_unstemmed PLGA Microspheres as new strategy to improve the efficiency of venom immunotherapy
title_sort PLGA Microspheres as new strategy to improve the efficiency of venom immunotherapy
author Trindade, R eginaldo Almeida da
author_facet Trindade, R eginaldo Almeida da
Sant’Anna, Osvaldo Augusto Brazil Esteves
Rescia, Vanessa Cristina
Bruni, Fernanda Miriani
Lopes-Ferreira, Mônica Valdyrce dos Anjos
Santos, Daiane Fernanda dos
Nicolete, Roberto
Faccioli, Lucia Helena
Araujo, Pedro Soares de
Costa, Maria Helena Bueno da
author_role author
author2 Sant’Anna, Osvaldo Augusto Brazil Esteves
Rescia, Vanessa Cristina
Bruni, Fernanda Miriani
Lopes-Ferreira, Mônica Valdyrce dos Anjos
Santos, Daiane Fernanda dos
Nicolete, Roberto
Faccioli, Lucia Helena
Araujo, Pedro Soares de
Costa, Maria Helena Bueno da
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Trindade, R eginaldo Almeida da
Sant’Anna, Osvaldo Augusto Brazil Esteves
Rescia, Vanessa Cristina
Bruni, Fernanda Miriani
Lopes-Ferreira, Mônica Valdyrce dos Anjos
Santos, Daiane Fernanda dos
Nicolete, Roberto
Faccioli, Lucia Helena
Araujo, Pedro Soares de
Costa, Maria Helena Bueno da
dc.subject.por.fl_str_mv Hipersensibilidade
Hypersensitivity
Imunoterapia
Immunotherapy
topic Hipersensibilidade
Hypersensitivity
Imunoterapia
Immunotherapy
description Background: Despite considerable knowledge of allergy and its physiopathology, the only treatment with long - lasting effects for bee venom (BV) allergic patients is venom immunotherapy (VIT). Its efficiency has been recognized worldwide for many years. Howe ver, some limitations still result in patient rejection and prevent its use, such as the long treatment period with a total of 30 - 80 injections administered over three to five years, the high cost of treatment, and the risk of anaphylaxis as a side effect. Objective: In order to overcome these inconveniences, a new formulation for VIT is proposed, consisting of BV encapsulated within microspheres composed of poly - lactide - co - glycolide (MS - PLGA) as a controlled delivery system. Methods: BV - MS - PLGA was prepare d by a double emulsion/solvent evaporation method and its biological efficiency was tested by ex vivo macrophage uptake stimuli and in vivo antibody production in mice. Results: BV - MS - PLGA formulations prevented inflammatory reactions by impeding direct co ntact between BV and the organism/tissue. The increased phagocytosis rate of BV - MS - PLGAs by macrophages allowed for the delivery of antigens directly to the intracellular environment. Furthermore, with the use of BV - MS - PLGAs, antibody production was compar able to traditional VIT (free BV delivered in PBS) with the advantages of protecting the organism against the deleterious effects of BV toxins and reducing the number of injections needed to produce the same protective effect. Conclusion: MS - PLGA is a prom ising controlled delivery system to deliver BV for VIT.
publishDate 2017
dc.date.none.fl_str_mv 2017-10-13T14:48:29Z
2017-10-13T14:48:29Z
2017
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv TRINDADE, R. A. da et al. PLGA microspheres as new strategy to improve the efficiency of venom immunotherapy. Journal of Chemical and Pharmaceutical Research, v. 9, n. 3, p. 197-208, 2017.
0975 - 7384
http://www.repositorio.ufc.br/handle/riufc/26626
identifier_str_mv TRINDADE, R. A. da et al. PLGA microspheres as new strategy to improve the efficiency of venom immunotherapy. Journal of Chemical and Pharmaceutical Research, v. 9, n. 3, p. 197-208, 2017.
0975 - 7384
url http://www.repositorio.ufc.br/handle/riufc/26626
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Journal of Chemical and Pharmaceutical Research
publisher.none.fl_str_mv Journal of Chemical and Pharmaceutical Research
dc.source.none.fl_str_mv reponame:Repositório Institucional da Universidade Federal do Ceará (UFC)
instname:Universidade Federal do Ceará (UFC)
instacron:UFC
instname_str Universidade Federal do Ceará (UFC)
instacron_str UFC
institution UFC
reponame_str Repositório Institucional da Universidade Federal do Ceará (UFC)
collection Repositório Institucional da Universidade Federal do Ceará (UFC)
repository.name.fl_str_mv Repositório Institucional da Universidade Federal do Ceará (UFC) - Universidade Federal do Ceará (UFC)
repository.mail.fl_str_mv bu@ufc.br || repositorio@ufc.br
_version_ 1813028946849038336